Chronic neutrophilic leukemia (CNL) is a very rare myeloid neoplasm characterized by peripheral blood neutrophilia and a hypercellular marrow with increased granulopoiesis. An activating mutation in CSF3R is present in 80% to 90% of cases. CNL displays some biological overlap in terms of clinical presentation and behavior, as well as genetic profile, with several other myeloid neoplasms, particularly myelodysplastic/myeloproliferative neoplasms (MDS/MPN) and other MPN. Distinguishing these related entities can be challenging, requires close attention to peripheral blood and bone marrow morphology, and can be informed by the mutation pattern: CNL is strongly associated with CSF3R mutation, usually lacks JAK2, MPL, or CALR mutations, and, by definition, lacks BCR::ABL1 rearrangement. Pitfalls in diagnosis include subjectivity in assessing neutrophil dysplasia and distinguishing true neoplastic neutrophilia from reactive neutrophilias that may be superimposed upon or occur as a manifestation of the progression of other myeloid neoplasms. Accurate distinction between neutrophilic myeloid neoplasms is important, as it helps guide patient management and may disclose specific genetic lesions amenable to targeted therapy.

1.
Szuber
N
,
Orazi
A
,
Tefferi
A.
Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management
.
Am J Hematol
.
2024
;
99
(
7
):
1360
-
1387
.
2.
Maxson
JE
,
Gotlib
J
,
Pollyea
DA
, et al.
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML
.
N Engl J Med
.
2013
;
368
(
19
):
1781
-
1790
.
3.
Szuber
N
,
Elliott
M
,
Tefferi
A.
Chronic neutrophilic leukemia: 2022 update on diagnosis, genomic landscape, prognosis, and management
.
Am J Hematol
.
2022
;
97
(
4
):
491
-
505
.
4.
Pardanani
A
,
Lasho
TL
,
Laborde
RR
, et al.
CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia
.
Leukemia
.
2013
;
27
(
9
):
1870
-
1873
.
5.
Zhang
H
,
Reister Schultz
A
,
Luty
S
, et al.
Characterization of the leukemogenic potential of distal cytoplasmic CSF3R truncation and missense mutations
.
Leukemia
.
2017
;
31
(
12
):
2752
-
2760
.
6.
Liongue
C
,
Ward
AC
.
Myeloproliferative neoplasms: diseases mediated by chronic activation of signal transducer and activator of transcription (STAT) proteins
.
Cancers (Basel)
.
2024
;
16
(
2
):
314
.
7.
Maxson
JE
,
Tyner
JW
.
Genomics of chronic neutrophilic leukemia
.
Blood
.
2017
;
129
(
6
):
715
-
722
.
8.
Gao
J
,
Han
S
,
Deng
B
,
Deng
Y
,
Gao
X.
Research progress of additional pathogenic mutations in chronic neutrophilic leukemia
.
Ann Hematol
.
2024
;
103
(
8
):
2591
-
2600
.
9.
Carreño-Tarragona
G
,
Álvarez-Larrán
A
,
Harrison
C
, et al.
CNL and aCML should be considered as a single entity based on molecular profiles and outcomes
.
Blood Adv
.
2023
;
7
(
9
):
1672
-
1681
.
10.
Elliott
MA
,
Pardanani
A
,
Hanson
CA
, et al.
ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia
.
Am J Hematol
.
2015
;
90
(
7
):
653
-
656
.
11.
Szuber
N
,
Finke
CM
,
Lasho
TL
, et al.
CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival
.
Blood Cancer J
.
2018
;
8
(
2
):
21
.
12.
Dao
KT
,
Gotlib
J
,
Deininger
MMN
, et al.
Efficacy of ruxolitinib in patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia
.
J Clin Oncol
.
2020
;
38
(
10
):
1006
-
1018
.
13.
Vermeersch
G
,
Delforge
M
,
Havelange
V
,
Graux
C
,
Michaux
L
,
Devos
T.
Case report: chronic neutrophilic leukemia associated with monoclonal gammopathies. A case series and review of genetic characteristics and practical management
.
Front Oncol
.
6
December
2022
;
12
:
1014671
.
14.
Otieno
SB
,
Altahan
A
,
Karri
S
,
Kaweeta
F
,
Lands
L
,
Weir
A.
CIN or not: an approach to the evaluation and management of chronic idiopathic neutrophilia
.
Blood Rev
.
March
2021
;
46
:
100739
.
15.
Plo
I
,
Zhang
Y
,
Le Couédic
JP
, et al.
An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia
.
J Exp Med
.
2009
;
206
(
8
):
1701
-
1707
.
16.
Link
DC
.
Mechanisms of leukemic transformation in congenital neutropenia
.
Curr Opin Hematol
.
2019
;
26
(
1
):
34
-
40
.
17.
Horwitz
MS
,
Corey
SJ
,
Grimes
HL
,
Tidwell
T.
ELANE mutations in cyclic and severe congenital neutropenia: genetics and pathophysiology
.
Hematol Oncol Clin North Am
.
2013
;
27
(
1
):
19
-
41
, vii.
18.
Pane
F
,
Frigeri
F
,
Sindona
M
, et al.
Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction)
.
Blood
.
1996
;
88
(
7
):
2410
-
2414
.
19.
Zhang
H
,
Wilmot
B
,
Bottomly
D
, et al.
Genomic landscape of neutrophilic leukemias of ambiguous diagnosis
.
Blood
.
2019
;
134
(
11
):
867
-
879
.
20.
Prakash
S
,
Arber
DA
,
Bueso-Ramos
C
,
Hasserjian
RP
,
Orazi
A.
Advances in myelodysplastic/myeloproliferative neoplasms
.
Virchows Arch
.
2023
;
482
(
1
):
69
-
83
.
21.
Bezerra
ED
,
Lasho
TL
,
Finke
CM
, et al.
CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes
.
Blood Cancer J
.
2021
;
11
(
3
):
54
.
22.
Guastafierro
V
,
Ubezio
M
,
Manes
N
,
Milanesi
C
,
Della Porta
M
,
Bonometti
A.
CSF3R-mutant chronic myelomonocytic leukemia is a distinct clinically subset with abysmal prognosis: a case report and systematic review of the literature
.
Leuk Lymphoma
.
2023
;
64
(
9
):
1566
-
1573
.
23.
Nm
H
,
Tam
W
,
Philipovskiy
A
,
Tonk
V
,
Orazi
A.
Myelodysplastic syndrome transforming to atypical chronic myeloid leukemia shows changes in its mutation allele frequency and acquisition of new mutations
.
Leuk Res Rep
.
2021
;
15
(
1
):
100248
.
24.
Obiorah
IE
,
Patel
BA
,
Groarke
EM
, et al.
Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1
.
Blood Adv
.
2021
;
5
(
16
):
3203
-
3215
.
25.
Phan
L
,
Hammond
D
,
Wilson
NR
,
Groarke
EM
,
Patnaik
MM
,
Pemmaraju
N.
VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic): clinical review in a rapidly emerging field [published online 21 May 2024]
.
Leuk Lymphoma
.
26.
Boddu
P
,
Chihara
D
,
Masarova
L
,
Pemmaraju
N
,
Patel
KP
,
Verstovsek
S.
The co-occurrence of driver mutations in chronic myeloproliferative neoplasms
.
Ann Hematol
.
2018
;
97
(
11
):
2071
-
2080
.
27.
Tashakori
M
,
Khoury
JD
,
Routbort
MJ
, et al.
Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations
.
Mod Pathol
.
2022
;
35
(
11
):
1677
-
1683
.
28.
Patel
AB
,
Franzini
A
,
Leroy
E
, et al.
JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera
.
Blood
.
2019
;
134
(
26
):
2388
-
2398
.
29.
Duncavage
EJ
,
Bagg
A
,
Hasserjian
RP
, et al.
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia
.
Blood
.
2022
;
140
(
21
):
2228
-
2247
.
30.
Freyer
CW
,
Hughes
ME
,
Carulli
A
,
Bagg
A
,
Hexner
E.
Pemigatinib for the treatment of myeloid/lymphoid neoplasms with FGFR1 rearrangement
.
Expert Rev Anticancer Ther
.
2023
;
23
(
4
):
351
-
359
.
31.
Hasserjian
RP
.
Illuminating neutrophilic myeloid neoplasms
.
Blood
.
2019
;
134
(
11
):
846
-
848
.
32.
Arber
DA
,
Orazi
A
,
Hasserjian
RP
, et al.
International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data
.
Blood
.
2022
;
140
(
11
):
1200
-
1228
.
33.
Khoury
JD
,
Solary
E
,
Abla
O
, et al.
The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms
.
Leukemia
.
2022
;
36
(
7
):
1703
-
1719
.
You do not currently have access to this content.